Skip to main content

Table 5 Summary of the recent studies on stereotactic body radiation therapy or 2-week schedule of hypofractionated radiotherapy for hepatocellular carcinoma

From: Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma

Author (year) Design No. of pts. Clinical condition & indication Dose prescription, median (range), Gy/fractions LC, % OS, % Toxicity
PVTT Tumor size, median (range), cm CP class    Liver GI
Andolino [9] (2011) Phase I/II 60 NA 3.1 (1.0–6.5) A,B CP-A: 44/3 (30–48)
CP-B: 40/5 (24–48)
90 (2Y) 67 (2Y) CP class change: 20%
(A➔B: 12%, B➔A: 8%)
Hepatic failure: 7% (all with a CP score ≥ 8)
No GI toxicity ≥ G3
Kang [12] (2012) Phase II 47 Yes
(11%)
2.9 (1.3–7.8) (sum of size) A,B7 57/3 (42–60/3) 95 (2Y) 69 (2Y) No RILD
CP class change A➔B: 13%
GI toxicity G3: 6%
Gastric ulcer G4: 4%
Yoon [8] (2013) Retro 93 No 2 (1.0–6.0) A, B 45/3 (30–60/3–4) 95 (1Y)
92 (3Y)
86 (1Y)
54 (3Y)
RILD ≥ G2: 18% (≥ G3: 7%)
Worsening of CP score ≥ 2: 10%
No bleeding or perforation
Sanuki [7] (2014) Retro 185 NA CP-A: 2.4 (0.5–5.0)
CP-B: 2.7 (1.0–5.0)
A, B CP-A: 40/5
CP-B: 35/5
99 (1Y)91 (3Y) 95 (1Y)
70 (3Y)
Worsening of CP score ≥ 2: 10%
G5 hepatic failure: 1%
NA
Huertas [21] (2015) Retro 77 NA 2.4 (0.7–6.3) A, B8 45/3 99 (1Y)
97 (3Y)
99 (1Y)
84 (3Y)
RILD: 5% Gastric ulcer G3: 1%, G4: 1%
Colic ulcer G2: 1%
Katz [25] (2011) Retro 18 No 4.0 (1.2–6.5) A, B, C 50/10 9% of patients developed a new lesion within 12 months after transplantation 100% after LT and/or hepatic resection
(median follow up 19.6 months)
Elevated liver enzyme G3: 5.6% No GI toxicity ≥ G3
Bae [24] (2012) Retro 20 No <  5 cm
(≤ 3 cm: 80%, > 3 cm: 20%)
A,B 50/10 85 (2Y) 88 (2Y) No RILD ≥ G3 GI toxicity G1: 30%
No GI toxicity ≥ G3
Present study Retro 77 No 2.4 (0.8–5.6) A, B 50/10 (35–50/10) 80 (3Y)
73 (5Y)
52 (3Y)
41 (5Y)
Worsening of CP score ≥ 2: 5.2% GI bleeding G3: 1.3%
  1. Abbreviations: CP Child-Pugh, G grade, GI gastrointestinal, HCC hepatocellular carcinoma, LC local control, NA not available, OS overall survival, PVTT portal vein tumor thrombus, Retro, retrospective, RILD radiation-induced liver disease